Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks

OBJECTIVE: To investigate whether addition of three different doses of liraglutide to insulin in patients with type 1 diabetes (T1D) results in significant reduction in glycemia, body weight, and insulin dose. RESEARCH DESIGN AND METHODS: We randomized 72 patients (placebo = 18, liraglutide = 54) wi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Diabetes Care
Hlavní autoři: Kuhadiya, Nitesh D., Dhindsa, Sandeep, Ghanim, Husam, Mehta, Aditya, Makdissi, Antoine, Batra, Manav, Sandhu, Sartaj, Hejna, Jeanne, Green, Kelly, Bellini, Natalie, Yang, Min, Chaudhuri, Ajay, Dandona, Paresh
Médium: Artigo
Jazyk:Inglês
Vydáno: American Diabetes Association 2016
Témata:
Emerging Technologies and Therapeutics
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5864130/
https://ncbi.nlm.nih.gov/pubmed/27208343
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc15-1136
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky